Results and Discussions: There were no difference between groups about demografic data, duration of scan and hemodynamic parameters. There was no significant difference in imaging quality between study groups. No signif- icant differences were found in the incidence of PONV. Induction times and recovery times were significantly shorter in the sevoflurane group than in the propofol group (p  0.05). Conclusion: Propofol or sevoflurane with larengeal mask provides satisfactory anesthesia during MRI in children. Sevoflurane provides more rapid induction and recovery than propofol. 10AP3-5 A pharmacokinetic study of i.v. tramadol continuous infusion in children A. Rochette, J. Ouaki, O. Raux, Ch. Dadure, X. Capdevila Hôpital Lapeyronie, Department of Anesthesia & critical care, CHU de Montpellier, Montpellier, France Background and Goal: Clinical studies encourage the use of i.v. tramadol (T) in children for post operative pain relief (1), but pharmacokinetic data remain rare. Stereo-selective plasma concentration and elimination profile of T and its main metabolite, O-desmethyl-T (ODT), i.e (+) & (-) enantiomers, were determined after 24-h T infusion. Methods: 24 children, 3.76 +/- 1.9 yrs, 15.8 +/- 5.5 kg, 0.66 +/- 0.16 m 2 , underwent gastro-oesophageal reflux laparoscopic surgery under standard anesthetic conditions. They received T, 2 mg/kg in 10 min, followed by 8 mg/kg as a 24-h continuous infusion and 1 mg/kg bolus if CHIPPS was 3 (max 5 times). 1.5 ml plasma sample was taken at 0.3, 12 & 24 h during and 0.25, 0.5, 1, 2, 4, 6 & 12 h after infusion for HPLC assay using tandem mass spec- trometry detection. Pk-fit software was used for pharmacokinetic analysis (2). Results: 18 patients received bolus T, 17 within 1.5h of initial dose, 6 had 2 to 4 boluses. Infusion resulted in a steady state for T+, T-, ODT+, ODT - plasma concentrations. Pharmacokinetic data are reported in the table. Plasma conc VDss Clearance t 1/2 ng/ml (H 2 4) l l/h h ( + ) tramadol mean(SD) 166.9 (77.1) 51 (32.8) 13.3 (5.9) 2.6 (.79) range 73.4–390 7.7–159 5.24–27.1 1.0–4.1 ( - ) tramadol mean(SD) 169.9 (69.3) 53 (30.1) 14.5 (6.6) 2.5 ( .7) range 62.7–350 7.9–126 5.69–28.2 .96–3.8 ( + ) ODT mean(SD) 26.2 (13) 852(822) 121 (103) 4.7 (1.4) range 4.51–54.1 248–3563 49.5–499 2.8–7.7 ( - ) ODT mean(SD) 32.8 (15.2) 539 (417) 86.7 (52) 4.14 (1) range 8.11–86.9 180–1984 23.4–278 2.31–5.8 ( - ) ODT clearance correlated to body surface (p = 0 .035). Conclusions: 1 – no accumulation of T or ODT occurred. 2 – no kinetic dif- ference appeared between enantiomers of both T and ODT. 3 – data were com- parable to adults. 4 – t 1/2 (ODT) is about twice t 1/2 (T). 5 – clinically relevant kinetic-demographic correlations were not found. References: 1 Bozkurt P. Pediatr anesth 2005. 15: 1041–7. 2 Farenc C et al. Comput biomed res 2000. 33; 315–30. 10AP3-6 The role of octreotide in the treatment of pancreatic pseudocyst in pediatric patients I. Budic, A. Slavkovic, D. Simic, V. Djordjevic, D. Novakovic Anesthesiaology Department, Clinic for Pediatric Surgery and Orthopedics, Clinical Centre Nis, Serbia, Nis, Serbia Background and Goal of Study: Pancreatic pseudocysts in children are rare and known as complications of acute pancreatitis and pancreatic trauma. Lately, the use of somatostatin and its long-acting analogue octreotide have proved useful in the treatment of pancreatc pseudocysts in children. Materials and Methods: In a recent multicenter randomized controlled study we investidgated the effects of short and long-term treatment of pancre- atic pseudocysts with octreotide. Complete records were available for 9 patients. Data pertaining to their admission, plus long-term radiologic and clinical outcome were analyzed. All patients were treated with octreotide acetate (2–3 g/kg SQ QD). Results and Discussions: Five children were treated conservatively with bowel rest and hyperalimentation. Two patients required percutaneous drainage, one patient needed surgical intervention. One patient had abdom- inal pain and surgical re-intervention not related to the pancreatic injury. The median length of hospitalization was 22 days. In three children significant decrease of the pseudocyst size was noticable 7 days after the conservative treatment with octreotide acetate, with almost complete resolution of the pseudocysts occurred within 6 weeks. Conclusion(s): Octreotide is a safe and potentially effective adjunct in the treatment of pediatric pancreatic pseudocyst, by which means surgical re-intervention could be avoided. References: 1) Uhl W, Anghelacopoulos SE, Friess H, Buchler MW. Digestion 1999; Suppl 2:23–31. 2) Cheruvu CV, Clarke MG, Prentice M, Eyre-Brook IA. Ann R Coll Surg Engl 2003; 85(5):313–6. 10AP3-7 Paediatric propofol pharmacokinetics: a multicentre study A. Rigby-Jones, M.J. Priston, A.R. Wolf, J.R. Sneyd Anaesthesia Research Group, Peninsula Medical School, Plymouth, United Kingdom Background and Goal of Study: Schuttler and Imhsen’s propofol pharma- cokinetic (PK) model 1 based on pooled adult and paediatric data lacked information for the smallest patients. We conducted a pooled population analysis of available neonatal and paediatric propofol PK data. The variable clinical circumstances of the individual studies allowed us to explore health status as a covariate. Materials and Methods: We combined propofol blood /plasma concentration vs. time data, dosing information and demographic data from 8 paediatric studies conducted by 6 research groups, with our data 2,3 . The pooled data set comprised 197 individuals (2315 observations), aged 0.02 to 12.25 years (2.75 to 60.5 kg, median 15 kg). In this preliminary PK analysis using NONMEM, the basic model structure was established before all model parameters were allometrically scaled to body weight. The influence of health status on paedi- atric propofol PK was explored. Results and Discussions: In this 3-compartment preliminary model, post- cardiac surgery patients have significantly reduced metabolic clearance rates (31 to 45% less when compared to healthy children or non-cardiac PICU patients). The volume of the deep peripheral compartment in critically ill and post-cardiac surgery children is 319% and 205% larger, respectively, than in healthy children, see Table 1. Table 1. PK values for a child weighing 15 kg Parameter Typical Value 95% CI CL (L/min) Healthy 0.614 0.563–0.665 PICU 0.767 0.628–0.906 PICU cardiac 0.421 0.366–0.476 Q2 (L/min) 0.839 0.703–0.975 Q3 (L/min) 0.252 0.221–0.283 V1 (L) 7.76 6.33–9.19 V2 (L) 14.4 12.8–16.0 V3 (L) Healthy 83.9 61.4–106 PICU 268 183–353 PICU cardiac 172 117–227 Conclusion(s): Health status may materially influence paediatric propofol PK. References: 1 Schuttler J, Ihmsen H Anesthesiology 2000; 92: 727–38. 2 Rigby-Jones AE et al Anesthesiology 2002; 97: 1393–400. 3 Murray DM et al. Paediatr Anaesth 2004; 14: 143–51. 10AP4-1 Behavioral reinforcement and play in paediatric outpatients: effects on anxiety, parental separation and induction A. Dutta, S.K. Malhotra, J. Sood, D. Kumar Anaesthesiology, Pain and Perioperative Medicine, Sir Ganga Ram Hospital, New Delhi, India Background and Goal of study: Coping skills, modeling and play are effec- tive behavioral modalities in decreasing preoperative anxiety amongst pedi- atric inpatients. In outpatient setting, these may be inadequate and difficult to apply. This investigation determines the effectiveness of behavioral rein- forcement with play versus play alone, in respect to anxiety, parental sepa- ration and induction in pediatric outpatients. Material and Methods: Thirty two children aged 3–7 years, of either sex were randomly divided into two groups: play with behavioral reinforcement (n = 16, group I) and play alone (n = 16, group II). Standardised measures for anxiety assessment were applied in the outpatient clinic and pre-anaesthesia Paediatric anaesthesia and intensive care 133